Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Germ Cell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    67 result(s) found for: Germ Cell. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2014-005095-28 Sponsor Protocol Number: IRST186.02 Start Date*: 2015-04-16
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Olaparib as salvage treatment for cisplatin-resistant germ cell tumor.
    Medical condition: cisplatin-resistant germ cell tumor
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000589-31 Sponsor Protocol Number: NEMESIS Start Date*: 2018-02-02
    Sponsor Name:SOCIETà CAMPANA DI IMMUNOTERAPIA ONCOLOGICA
    Full Title: multi stage phase II trial of Nivolumab (an anti –PD-1) in patients with platinum resistant Mismatch Repair deficient germinal cells tumours
    Medical condition: patients with platinum resistant Mismatch Repair deficient germinal cells tumours
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000618-35 Sponsor Protocol Number: M07PGC Start Date*: 2007-11-29
    Sponsor Name:Rigshospitalet
    Full Title: PHASE II TRIAL OF PACLITAXEL, GEMCITABINE AND CISPLATIN IN PATIENTS WITH RELAPSING GERM CELL CANCER AFTER FIRST LINE CHEMOTHERAPY
    Medical condition: · The primary objective of this study is to investigate the combination of cisplatin/gemcitabine/paclitaxel, with respect to progression free survival in patients with germ cell tumours previously...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing) DK (Ongoing) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-015400-26 Sponsor Protocol Number: ARQ 197-A-U251 Start Date*: 2010-03-04
    Sponsor Name:Daiichi Sankyo Pharma Development
    Full Title: MULTICENTER PHASE 2 TRIAL OF ARQ 197 FOR SUBJECTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS
    Medical condition: Germ cell tumors (GCT) including testicular and non-central nervous system (non-CNS) extragonadal types.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10061184 Germ cell cancer LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004667-61 Sponsor Protocol Number: SUITE - CUOG-TE 05 Start Date*: 2007-02-22
    Sponsor Name:Universitätsklinikum Hamburg-Eppendorf
    Full Title: Prospective open-labeled non randomized Phase-II study of SU011248 (Sunitinib) in male patients with relapsed or cisplatin-refractory germ cell cancer - A CUOG/GTCSG cooperative phase II study
    Medical condition: germ cell cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061378 Testicular germ cell cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004508-36 Sponsor Protocol Number: FM-12-GCT01 Start Date*: 2013-05-04
    Sponsor Name:Fondazione Michelangelo - Avanzamento dello studio e cura dei tumori
    Full Title: Brentuximab vedotin (SGN-35) as salvage therapy for males with advanced and platinum-resistant germ-cell tumors. An open label, single group, Phase 2 trial
    Medical condition: Patients with histologically-confirmed germ-cell cancer with exclusive or prevalent CD30-positive embryonal carcinoma component
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061378 Testicular germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000731-28 Sponsor Protocol Number: EORTC 30983 Start Date*: 2006-03-23
    Sponsor Name:EORTC
    Full Title: A Randomised Phase II/III Study of Taxol-BEP Versus BEP in Patients with Intermediate Prognosis Germ Cell Cancer
    Medical condition: Patients with Intermediate Prognosis Germ cell Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061378 LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004632-38 Sponsor Protocol Number: GCTSK005 Start Date*: 2017-11-09
    Sponsor Name:Národný onkologický ústav
    Full Title: Phase II study of Avelumab in multiple relapsed/refractory testicular germ cell cancer.
    Medical condition: Extracranial primary germ cell cancer, seminoma, or nonseminoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061378 Testicular germ cell cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039956 Seminoma PT
    20.0 100000021189 10029557 Non-seminoma testicular cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-021898-36 Sponsor Protocol Number: INT 38/10 Start Date*: 2010-10-20
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Tandem high-dose chemotherapy (HDCT) with peripheral-blood stem-cell rescue for patients with metastatic germ-cell tumors failing first-line treatment.
    Medical condition: Patients with metastatic germ-cell tumors failing first-line treatment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043302 LLT
    9.1 10061378 LLT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004418-32 Sponsor Protocol Number: TestisCAB Start Date*: 2016-03-16
    Sponsor Name:Oslo University Hospital - Cancer Department
    Full Title: Cabazitaxel as salvage treatment for cisplatin-resistant germ cell cancer.
    Medical condition: Cisplatin-resistant germ cell cancer of the testicle or extragonadal GCC originating from retroperitoneum or mediastinum.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055103 Testicular cancer metastatic PT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed) DK (Ongoing) SE (Ongoing) NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000405-22 Sponsor Protocol Number: TE23 Start Date*: 2005-02-25
    Sponsor Name:Medical Research Council
    Full Title: TE23: Randomised Phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP chemotherapy in poor prognosis male germ cell tumours.
    Medical condition: Poor prognosis male germ cell tumours
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043333 Testicular germ cell tumour mixed stage III LLT
    9.1 10015802 Extragonadal primary germ cell tumour mixed stage III LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005068-14 Sponsor Protocol Number: 08GENH 06 Start Date*: 2013-07-12
    Sponsor Name:Institut Claudius Regaud
    Full Title: Etude de phase II d’intensification de dose dans les tumeurs germinales réfractaires et en rechute de mauvais pronostic Protocole TICE : Paclitaxel et Ifosfamide suivi par une intensification de C...
    Medical condition: tumeurs germinales réfractaires en rechute
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004141-17 Sponsor Protocol Number: Start Date*: 2020-08-07
    Sponsor Name:Children's Oncology Group
    Full Title: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
    Medical condition: Ovarian, Testicular, or Extragonadal germ cell tumours
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015800 Extragonadal primary germ cell tumour mixed stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015801 Extragonadal primary germ cell tumour mixed stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015802 Extragonadal primary germ cell tumour mixed stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043331 Testicular germ cell tumour mixed stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043332 Testicular germ cell tumour mixed stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043333 Testicular germ cell tumour mixed stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004433 Benign ovarian tumour PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006032 Borderline ovarian tumour PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-018072-33 Sponsor Protocol Number: UKM08_0057 Start Date*: 2011-08-01
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Prospective Trial for the diagnosis and treatment of children, adolescents and young adults with Intracranial Germ Cell Tumours
    Medical condition: Intracranial Germ Cell tumours of any histology and intracranial site and dissemination
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065853 Nongerminomatous germ cell tumor of the CNS LLT
    20.0 100000004864 10018207 Germinoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) GB (Completed) FR (Completed) AT (Completed) IT (Ongoing) BE (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-001502-10 Sponsor Protocol Number: GCTSK002 Start Date*: 2011-09-28
    Sponsor Name:National Cancer Institute
    Full Title: Phase II study of Everolimus in refractory testicular germ cell cancer.
    Medical condition: refractory metastatic germ cell tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-014383-18 Sponsor Protocol Number: CRAD001CDE21T Start Date*: 2010-08-12
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer
    Medical condition: Germ cell tumor, metastatic, relapsed or refractory
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055103 Testicular cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004981-42 Sponsor Protocol Number: GCTSK001 Start Date*: 2008-01-17
    Sponsor Name:Narodny onkologicky ustav
    Full Title: Phase II study of sunitinib malate (SUTENT®) in relapsed germ cell tumors in males.
    Medical condition: germ cell tumor
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2016-001688-35 Sponsor Protocol Number: APACHE Start Date*: 2016-09-09
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, alone or in combination with Tremelimumab, in patients with advanced and relapsed germ cell tumors
    Medical condition: Advanced and relapsed germ cell tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068971 Germ cell cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003930-17 Sponsor Protocol Number: 1407-GUCG Start Date*: 2015-10-05
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLO...
    Medical condition: progressive or recurrent germ cell tumor (measurable or non-measurable)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10043338 Testicular malignant germ cell tumor NOS LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: BE (Ongoing) DK (Ongoing) IE (Ongoing) FR (Ongoing) NL (Ongoing) SI (Completed) ES (Ongoing) DE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003060-37 Sponsor Protocol Number: ANZUP1302 Start Date*: 2017-04-05
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: UK P3BEP - A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
    Medical condition: International germ cell classification catergory (IGCCC) intermediate or poor-risk metastatic germ cell tumours
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068971 Germ cell cancer metastatic PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 03 08:26:37 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA